These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 9558174)
41. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Robertson LP; Davis MJ Rheumatology (Oxford); 2004 Dec; 43(12):1565-8. PubMed ID: 15353608 [TBL] [Abstract][Full Text] [Related]
42. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. Collantes-Estevez E; Muñoz-Villanueva MC; Zarco P; Torre-Alonso JC; Gratacós J; González C; Sanmartí R; Cañete JD; Rheumatology (Oxford); 2005 Dec; 44(12):1555-8. PubMed ID: 16118228 [TBL] [Abstract][Full Text] [Related]
43. Disease and psychological status in ankylosing spondylitis. Martindale J; Smith J; Sutton CJ; Grennan D; Goodacre L; Goodacre JA Rheumatology (Oxford); 2006 Oct; 45(10):1288-93. PubMed ID: 16595514 [TBL] [Abstract][Full Text] [Related]
44. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Marzo-Ortega H; McGonagle D; O'Connor P; Emery P Arthritis Rheum; 2001 Sep; 44(9):2112-7. PubMed ID: 11592375 [TBL] [Abstract][Full Text] [Related]
45. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Dougados M; Béhier JM; Jolchine I; Calin A; van der Heijde D; Olivieri I; Zeidler H; Herman H Arthritis Rheum; 2001 Jan; 44(1):180-5. PubMed ID: 11212158 [TBL] [Abstract][Full Text] [Related]
46. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. van Denderen JC; van der Paardt M; Nurmohamed MT; de Ryck YM; Dijkmans BA; van der Horst-Bruinsma IE Ann Rheum Dis; 2005 Dec; 64(12):1761-4. PubMed ID: 15901634 [TBL] [Abstract][Full Text] [Related]
47. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913 [TBL] [Abstract][Full Text] [Related]
48. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. Schatteman L; Gyselbrecht L; De Clercq L; Mielants H J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792 [TBL] [Abstract][Full Text] [Related]
49. Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures. Dagfinrud H; Vollestad NK; Loge JH; Kvien TK; Mengshoel AM Arthritis Rheum; 2005 Feb; 53(1):5-11. PubMed ID: 15696569 [TBL] [Abstract][Full Text] [Related]
50. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Heuft-Dorenbosch L; van Tubergen A; Spoorenberg A; Landewé R; Dougados M; Mielants H; van der Tempel H; van der Heijde D Arthritis Rheum; 2004 Apr; 51(2):154-9. PubMed ID: 15077254 [TBL] [Abstract][Full Text] [Related]
51. Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a placebo control trial in a tertiary level center. Sarkar RN; Phaujdar S; De D; Bhattacharyya K Rheumatol Int; 2012 Dec; 32(12):3945-50. PubMed ID: 22200806 [TBL] [Abstract][Full Text] [Related]
53. Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. Mok CC; Li OC; Chan KL; Ho LY; Hui PK Scand J Rheumatol; 2015; 44(6):480-6. PubMed ID: 26271141 [TBL] [Abstract][Full Text] [Related]
54. Development and validation of the Edmonton Ankylosing Spondylitis Metrology Index. Maksymowych WP; Mallon C; Richardson R; Conner-Spady B; Jauregui E; Chung C; Zappala L; Pile K; Russell AS Arthritis Rheum; 2006 Aug; 55(4):575-82. PubMed ID: 16874779 [TBL] [Abstract][Full Text] [Related]
55. The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis. Slobodin G; Rosner I; Rimar D; Boulman N; Rozenbaum M; Odeh M Clin Rheumatol; 2010 Jul; 29(7):793-4. PubMed ID: 20111975 [TBL] [Abstract][Full Text] [Related]
56. [Sulfasalazine in the treatment of ankylosing spondylitis]. Krajnc I Lijec Vjesn; 1990; 112(5-6):171-4. PubMed ID: 1978212 [TBL] [Abstract][Full Text] [Related]
57. Treatment of ankylosing spondylitis with pamidronate: an open label study. Grover R; Shankar S; Aneja R; Marwaha V; Gupta R; Kumar A Ann Rheum Dis; 2006 May; 65(5):688-9. PubMed ID: 16611869 [No Abstract] [Full Text] [Related]
58. [The efficacy and safety of long-term thalidomide in the treatment of ankylosing spondylitis]. Zhu J; Huang F; Zhang JL Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):667-70. PubMed ID: 20979785 [TBL] [Abstract][Full Text] [Related]
59. Treatment of the seronegative spondyloarthropathies with sulfasalazine. Zwillich SH; Comer SS; Lee E; Erdman WA; Lipsky PE J Rheumatol Suppl; 1988 Sep; 16():33-9. PubMed ID: 2903925 [TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of thalidomide on psychological symptoms and sleep disturbances in the patient with refractory ankylosing spondylitis. Zhang S; Chen Z; Wu Y; Lin D; He J; Liu J; Gao F; Lin H Ann Palliat Med; 2021 Mar; 10(3):2512-2519. PubMed ID: 33474948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]